BioCentury | Apr 21, 2014
Finance

European beachhead

...In 2012, Zalicus discontinued development of Synavive in RA after the selective steroid amplifier containing dipyridamole...
BioCentury | Nov 21, 2013
Targets & Mechanisms

Riding the integrin wave in thrombosis

...adenosine diphosphate receptor ) antagonist, to treat cardiovascular indications and stroke. Boehringer Ingelheim GmbH markets Aggrenox...
BioCentury | Sep 17, 2012
Analyst Picks & Changes

Analyst picks & changes

...from $4 on Zalicus' decision to discontinue development of Synavive. The selective steroid amplifier containing dipyridamole...
BioCentury | Sep 17, 2012
Clinical News

Synavive: Development discontinued

...6 weeks leading up to and throughout the study. Patients received once-daily placebo, Synavive, prednisolone, dipyridamole...
...Mass. Product: Synavive (Z-102) Business: Autoimmune Molecular target: Not available Description: Selective steroid amplifier containing dipyridamole...
BioCentury | Sep 11, 2012
Clinical News

Zalicus slides after dropping RA product

...in the Phase IIb SYNERGY trial to treat rheumatoid arthritis. The selective steroid amplifier containing dipyridamole...
BioCentury | May 7, 2012
Clinical News

Synavive: Completed Phase IIb enrollment

...placebo-controlled, international Phase IIb SYNERGY trial comparing once-daily Synavive vs. monotherapy with once-daily prednisolone, once-daily dipyridamole...
...Mass. Product: Synavive (Z-102) Business: Autoimmune Molecular target: Not available Description: Selective steroid amplifier containing dipyridamole...
BioCentury | Feb 23, 2012
Distillery Therapeutics

Indication: Renal disease

...acute kidney injury, Ent1 knockout mice or wild-type mice treated with the nonselective ENT1 antagonist dipyridamole...
BioCentury | Jul 4, 2011
Clinical News

Synavive: Phase IIb started

...international Phase IIb SYNERGY trial to compare once-daily Synavive vs. monotherapy with once-daily prednisolone, once-daily dipyridamole...
...Synavive ( Z-102 ) Business: Autoimmune Molecular target: Not available Description: Selective steroid amplifier containing dipyridamole...
BioCentury | Dec 20, 2010
Clinical News

Aggrenox/Asasantin Retard dipyridamole regulatory update

...U.K. (see BioCentury, Nov. 1). The guidance also recommends the use of Aggrenox/Asasantin Retard, a modified-release dipyridamole...
...U.K. (see BioCentury, Nov. 1). The guidance also recommends the use of Aggrenox/Asasantin Retard, a modified-release dipyridamole...
...dipyridamole; Plavix clopidogrel Business: Cardiovascular The guidance updates a 2005 NICE guidance, which previously recommended Aggrenox/Asasantin Retard...
BioCentury | Nov 1, 2010
Clinical News

Plavix clopidogrel regulatory update

...in line with an August preliminary appraisal, also recommends the use of Aggrenox/Asasantin Retard, a modified-release dipyridamole...
...only if clopidogrel is contraindicated or not tolerated (see BioCentury, Aug. 9). Persantin Retard, modified-release dipyridamole...
...sanofi-aventis Group (Euronext:SAN; NYSE:SNY), Paris, France Product: Plavix clopidogrel; Aggrenox / Asasantin Retard dipyridamole; Persantin Retard dipyridamole...
Items per page:
1 - 10 of 68